North China Pharmaceutical Joint Stock Company Pharmaceutical Plant Safety Assessment Report
Time：2016-08-13
|
From：
|
Views：216
|
Font Size：Default Big Large
|
Print
|
1. Name of safety assessment project:
North China pharmaceutical joint stock company pharmaceutical plant safety assessment report
2. Introduction to the safety assessment project:
The North China Pharmaceutical joint stock company Pharmaceutical Factory is located at No. 388, Heping East Road, Shijiazhuang City, the capital of Hebei Province. The predecessor of the North China Pharmaceutical Joint stock company Pharmaceutical Factory is a key construction project during China's "First Five-Year Plan" period. It is an antibiotic factory among 156 key projects aided by the former Soviet Union. The completion of the North China Pharmaceutical Factory created the history of large-scale production of antibiotics in our country and ended the history of relying on imports of penicillin and streptomycin in our country. Antibiotic production is at the advanced level in the country.
In June 2009, with the support of the State-owned Assets Supervision and Administration Commission of Hebei Province, Jizhong Energy restructured North China Pharmaceutical. It promoted the stable operation and further growth of North China Pharmaceutical, and developed into an enterprise group with multiple subsidiaries and multiple investment entities. North China Pharmaceutical joint stock company Pharmaceutical General Factory has cultivated and transported a large number of management talents, technical talents and high-quality workforce for its brother company by relying on its own technical advantages and talent advantages.
North China pharmaceutical joint stock company pharmaceutical plant fixed assets 1.976 billion RMB, covering an area of 240,000 m2, building area of 360,000 m2, 2000 through the ISO9001 quality system certification, 2003 through the ISO14000 environmental system certification, 2004 through the SA8000 social responsibility and occupational health management system certification, enterprises to strengthen their own safety management, many times the safety standardization of self-assessment, can meet the national safety standardization level three standards.
With the changes of the times and the changes of the market, the North China Pharmaceutical joint stock company now produces penicillin sodium and penicillin V potassium (the safety status evaluation in December 2011 included penicillin sodium, penicillin potassium, penicillin V potassium, oxytetracycline, norfomycin, 6-aminobenicillanic acid (6-APA), lycopene, soy isoflavones, ampicillin sodium, cefminocycline and other 10 products), so most of the workshops of the pharmaceutical factory have been discontinued, and the organizational structure of the corresponding pharmaceutical factory has also changed.
The pharmaceutical factory has 585 employees. The pharmaceutical factory has a comprehensive management center, a production support center, a safety management center, a quality assurance center, and a financial accounting center. 5 functional areas of business, 103 workshops (including the original 102 workshop recycling), 104 workshops 2 production workshops and 110 workshops, warehouses, and environmental protection 3 power auxiliary workshops.
Pharmaceutical General Factory in December 2011 by Hebei Huafei Science and Technology Consulting Co., Ltd. conducted a safety status evaluation, and obtained a filing opinion issued by Shijiazhuang City Safety Production Supervision and Administration Bureau (Shijiazhuang Hazard Safety Evaluation [2012] No. 6), valid period to December 2014.
Pharmaceutical General Factory in May 2011 by Hebei Huafei Technology Consulting Co., Ltd. compiled the "North China pharmaceutical joint stock company major hazard assessment report", and obtained the record certificate issued by Shijiazhuang Chang'an District Safety Production Supervision and Administration Bureau (certificate number: (Chang'an) safety supervision heavy preparation word [2011] YWH002), the record content is a four-level major hazard source.
The pharmaceutical factory was established earlier and has a compact layout. With the urban development of Shijiazhuang and the acceleration of urbanization, the pharmaceutical factory is gradually surrounded by residential areas and commercial stores, and the production of enterprises and residents' lives have a certain degree of influence on each other. To this end, the pharmaceutical factory has formulated an overall relocation plan, and the relocation work is currently actively in operation.
Although the pharmaceutical factory is facing relocation, it is still strictly managed in actual production to ensure production safety. There is a safety production committee, a safety production management network has been established, and the safety standardization system is continuously running. There is a full-time safety management organization - the Safety Management Center is responsible for the safety management of the pharmaceutical factory. There are 12 full-time safety management personnel. They have all passed the safety qualification training organized by the Safety Production Supervision and Administration Bureau and passed the assessment, and obtained the qualification of safety production management. The special operation personnel have been trained by relevant departments and obtained the certificate of conformity. The post staff have passed the Security Training organized by the unit and passed the assessment, and have the qualification for safety production.
The pharmaceutical factory has established a sound safety production responsibility system, safety management system, safety technical operation procedures, etc., and strictly implements them. Formulate emergency rescue plans for major accidents and conduct regular drills.
The products produced by the North China Pharmaceutical joint stock company are not dangerous chemicals, but the raw and auxiliary materials used include a variety of dangerous chemicals. Sulfuric acid, sodium hydroxide, hydrochloric acid, ammonia, n-butanol, butyl acetate, ethyl acetate, ethanol, nitrogen, liquid ammonia (refrigerant in refrigeration station) are all dangerous chemicals used in the production process of penicillin sodium and penicillin V potassium. In addition, the production process also uses the method of rectifying butyl acetate, n-butanol and other dangerous chemicals for recycling. According to the relevant provisions of the "Measures for the Implementation of Safety Production Licenses for Hazardous Chemical Production Enterprises" (Order No. 41 of the State Administration of Work Safety), the general pharmaceutical factory is a hazardous chemical production enterprise because it involves the recycling of butyl acetate and n-butanol hazardous chemicals during the production process.
3. Safety evaluation project leader, technical leader, process control leader, evaluation report compiler, report auditor, safety evaluator, registered safety engineer, and technical expert involved in the evaluation:
Safety evaluation project leader: Gao Weili
Technical person in charge: Cao Shuhua
Person in charge of process control: Wang Lin
Evaluation Report Compilers: Xu Zhe, Sun Guang, Wang Ying
Report Reviewer: Zhou Junhong
Safety evaluators, registered safety engineers, and technical experts participating in the evaluation work: Gao Weili, Xu Zhe, Sun Guang, Wang Ying, Zhou Junhong, Cao Shuhua
4. List of personnel, time, and main tasks to carry out safety evaluation work on site, and evaluation report time:
In November 2015, the North China pharmaceutical joint stock company entrusted Hebei Huafei Technology Consulting Co., Ltd. to undertake the safety evaluation of the factory. Safety evaluation of the company's production, storage and transportation equipment and public works, and signed a safety evaluation technical service contract.
This safety status evaluation is based on the company's surrounding relationships, general layout, production equipment, supporting public works and auxiliary facilities, safety management, etc. This safety status evaluation is mainly based on the checklist evaluation method. According to the current laws and regulations of the country, standards and norms are compared to identify non-conformities, so that enterprises can carry out rectification and improvement in a targeted manner. For dangerous and harmful factors with higher risk levels, risk assessment methods and major accident consequence simulation are used to quantitatively evaluate their risk level, providing a basis for enterprises to formulate emergency rescue plans and key prevention.
After solid work, the safety status evaluation report of this project was completed in December 2015.